Pair Name	Tetrandrine, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Up-regulation	Expression	BBC3	hsa27113
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	BCL2L11	KEGG ID N.A.
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BID	hsa637
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP8	hsa841
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
	Down-regulation	Expression	MCL1	hsa4170
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	BEL-7402	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_5492
	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vivo Model	All qualified mice were injected in the right flank with 2×10⁷ HCT116 cells suspended in 0.2 ml of PBS.
Result	The antitumour activity of sorafenib plus tetrandrine may be attributed to the induction of the intrinsic apoptosis pathway through ROS/Akt signaling. This finding provides a novel approach that may broaden the clinical application of sorafenib.